-+ 0.00%
-+ 0.00%
-+ 0.00%
Novo Nordisk's Wegovy cuts BMI 13.5% in children aged 6 to under 12 in Phase 3 trial
Share
Listen to the news
Novo Nordisk's Wegovy cuts BMI 13.5% in children aged 6 to under 12 in Phase 3 trial
  • Novo Nordisk announced Phase 3 STEP Young results showing Wegovy reduced obesity more than placebo in children aged 6 to under 12.
  • Treatment combined with lifestyle changes improved weight status, with some children no longer classified as having obesity.
  • No unexpected safety concerns emerged; researchers identified no safety concerns affecting growth or pubertal development.
  • Results were presented at ObesityWeek 2026 and published in The New England Journal of Medicine on November 16, 2026.
  • Semaglutide injection remains investigational for children under 12 and is not approved for that age group in the United States.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending